Table 2 Multivariable Cox proportional hazard models of RFS and OS

From: PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

Variable (contrast)

Recurrence-free survival

Overall survival

 

Hazard ratio

P-value

Hazard ratio

P-value

Number of positive nodes (sqrt)

2.17 (1.82, 2.60)

<0.0001

2.18 (1.82, 2.63)

<0.0001

Menopausal status (pre/post)

0.91 (0.75, 1.10)

0.3276

0.88 (0.72, 1.08)

0.2284

Dose density (q3wk/q2wk)

1.20 (0.99, 1.45)

0.0582

1.15 (0.94, 1.40)

0.1671

Sequence of therapy (con/seq)

0.98 (0.81, 1.18)

0.8314

0.98 (0.80, 1.19)

0.8174

PAM50 intrinsic subtype

 Basal-like versus LumA

1.83 (1.40, 2.38)

<0.0001

1.91 (1.44, 2.53)

<0.0001

 HER2-E versus LumA

1.63 (1.24, 2.15)

 

1.69 (1.27, 2.26)

 

 LumB versus LumA

1.47 (1.14, 1.91)

 

1.47 (1.12, 1.94)

 
  1. Abbreviations: con, concurrent; HER2-E, HER2-enriched; Lum, luminal; q2wk, every two weeks or 2-weekly; q3wk, every 3 weeks or 3-weekly; seq, sequential; sqrt, square root.
  2. N=1,299 because 11 patients were missing information about the number of positive nodes or menopausal status.
Back to article page